TYO:4892

3 stories mentioning TYO:4892

Every FINWIRES story that references TYO:4892, newest first.

Market Chatter: Cyfuse to Conduct First Human Trial of 3D-Printed Implant for Knee Repair

Keio University and Fujita Health University are collaborating with Cyfuse Biomedical (TYO:4892) to conduct the first clinical trial for a regenerative treatment that repairs damaged knee bone and cartilage, Nikkei Asia reported on Monday.The clinical trial uses a 3D-printed material made from cells harvested from human fat tissue, which is expected to offer a potential alternative to joint replacement surgery, the publication said.Starting as early as July, the trial will enroll five patients with idiopathic osteonecrosis of the knee, a condition that results in bone loss, the news agency said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

TYO:4892

Asia56d ago

Nikkei Advances as Fiscal Outlook Calms Rate Fears

Japanese stocks closed higher on Monday, supported by policy signals after an opposition party leader called for a medium-term fiscal roadmap to restore surplus by around 2030, easing concerns over rising interest rates.The Nikkei 225 rose 0.6%, or 348.99 points, to close at 58,824.89.Yuichiro Tamaki said Japan should outline a credible five-year path to return to a primary surplus by around 2030, while accepting near-term deficits.He also said monetary policy should move gradually toward normalization, with rate hikes calibrated carefully given risks from the Iran conflict.Markets have pared expectations for an April rate increase by the Bank of Japan amid uncertainty over the Middle East situation. The government has tapped oil reserves and is seeking alternative supply sources, though public concern over the economic impact remains high.In economic news, Japan's tertiary activity index fell 0.4% in February as weakness in retail and utilities offset gains in finance.Japanese household sentiment improved slightly in March but remained negative, with inflation expectations staying elevated, a Bank of Japan survey showed.On the corporate front, Komehyo Holdings (TYO:2780) fell 1% after reporting a 43% jump in March sales. Cyfuse Biomedical (TYO:4892) rose 12% after a report said it will begin human trials of a 3D-printed knee regeneration therapy.IwaiCosmo (TYO:8707) slipped 2% despite a 55% rise in full-year profit and record earnings.

Nikkei 225TYO:2780TYO:4892TYO:8707

Asia56d ago

Market Chatter: Cyfuse Moves 3D Cell-Based Knee Therapy Into Human Trials

Cyfuse Biomedical K.K (TYO:4892) is advancing its regenerative medicine platform into human trials, with a new therapy aimed at repairing knee bone and cartilage using 3D-printed cell constructs, Nikkei reported Monday.The physician-led study, conducted with Keio University and Fujita Health University, will test implants created from patients' own fat-derived cells. The trial, expected to begin as early as July, will enroll five patients with idiopathic osteonecrosis of the knee, according to the report.Cyfuse's technology produces scaffold-free, three-dimensional tissue using living cells, designed to integrate more naturally and lower rejection risk. The knee program marks a step toward addressing conditions where both bone and cartilage are damaged, an area with limited treatment options beyond joint replacement, the report said.The company has already validated safety in preclinical studies and is positioning the therapy as part of a broader pipeline in regenerative medicine. Earlier this year, Cyfuse began a separate clinical study focused on nerve repair using similar cell-based structures, according to the report.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

TYO:4892